Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2007;157(13-14):295-300.
doi: 10.1007/s10354-007-0427-5.
Affiliations
- PMID: 17704975
- DOI: 10.1007/s10354-007-0427-5
Randomized Controlled Trial
Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial
Andrey Scripnikov et al. Wien Med Wochenschr. 2007.
Abstract
In a randomised, double-blind, 22-week trial 400 patients with dementia associated with neuropsychiatric features were treated with Ginkgo biloba extract EGb 761 (240 mg/day) or placebo. Patients with probable Alzheimer's disease, possible Alzheimer's disease with cerebrovascular disease or vascular dementia were eligible if they scored 9 to 23 on the SKT cognitive test battery and at least 5 on the Neuropsychiatric Inventory (NPI). EGb 761 was significantly superior to placebo with respect to the primary (SKT test battery) and all secondary outcome variables. The mean composite score (frequency x severity) and the mean caregiver distress score of the NPI dropped from 21.3 to 14.7 and 13.5 to 8.7, respectively, in the EGb 761-treated patients, but increased from 21.6 to 24.1 and 13.4 to 13.9, respectively, under placebo (p < 0.001). The largest drug-placebo differences in favour of EGb 761 were found for apathy/indifference, anxiety, irritability/lability, depression/dysphoria and sleep/nighttime behaviour.
Similar articles
- Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial.
Napryeyenko O, Sonnik G, Tartakovsky I. Napryeyenko O, et al. J Neurol Sci. 2009 Aug 15;283(1-2):224-9. doi: 10.1016/j.jns.2009.02.353. Epub 2009 Mar 14. J Neurol Sci. 2009. PMID: 19286192 Clinical Trial. - Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial.
Napryeyenko O, Borzenko I; GINDEM-NP Study Group. Napryeyenko O, et al. Arzneimittelforschung. 2007;57(1):4-11. doi: 10.1055/s-0031-1296579. Arzneimittelforschung. 2007. PMID: 17341003 Clinical Trial. - Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg.
Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S. Herrschaft H, et al. J Psychiatr Res. 2012 Jun;46(6):716-23. doi: 10.1016/j.jpsychires.2012.03.003. Epub 2012 Mar 27. J Psychiatr Res. 2012. PMID: 22459264 Clinical Trial. - Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials.
Savaskan E, Mueller H, Hoerr R, von Gunten A, Gauthier S. Savaskan E, et al. Int Psychogeriatr. 2018 Mar;30(3):285-293. doi: 10.1017/S1041610217001892. Epub 2017 Sep 21. Int Psychogeriatr. 2018. PMID: 28931444 Review. - Effects of Ginkgo biloba extract EGb 761 ® in dementia with neuropsychiatric features: review of recently completed randomised, controlled trials.
Ihl R. Ihl R. Int J Psychiatry Clin Pract. 2013 Nov;17 Suppl 1:8-14. doi: 10.3109/13651501.2013.814796. Epub 2013 Aug 27. Int J Psychiatry Clin Pract. 2013. PMID: 23808613 Review.
Cited by
- Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment.
Pless A, Ware D, Saggu S, Rehman H, Morgan J, Wang Q. Pless A, et al. Front Neurosci. 2023 Sep 5;17:1263771. doi: 10.3389/fnins.2023.1263771. eCollection 2023. Front Neurosci. 2023. PMID: 37732300 Free PMC article. Review. - A Systematic Review of Pharmacological Interventions for Apathy in Aging Neurocognitive Disorders.
Theleritis C, Siarkos K, Politis A, Smyrnis N, Papageorgiou C, Politis AM. Theleritis C, et al. Brain Sci. 2023 Jul 12;13(7):1061. doi: 10.3390/brainsci13071061. Brain Sci. 2023. PMID: 37508993 Free PMC article. Review. - Pharmacological Management of Apathy in Dementia.
Azhar L, Kusumo RW, Marotta G, Lanctôt KL, Herrmann N. Azhar L, et al. CNS Drugs. 2022 Feb;36(2):143-165. doi: 10.1007/s40263-021-00883-0. Epub 2022 Jan 10. CNS Drugs. 2022. PMID: 35006557 Review. - The Use of Ginkgo Biloba L. as a Neuroprotective Agent in the Alzheimer's Disease.
Nowak A, Kojder K, Zielonka-Brzezicka J, Wróbel J, Bosiacki M, Fabiańska M, Wróbel M, Sołek-Pastuszka J, Klimowicz A. Nowak A, et al. Front Pharmacol. 2021 Nov 4;12:775034. doi: 10.3389/fphar.2021.775034. eCollection 2021. Front Pharmacol. 2021. PMID: 34803717 Free PMC article. Review. - Pharmacotherapies for sleep disturbances in dementia.
McCleery J, Sharpley AL. McCleery J, et al. Cochrane Database Syst Rev. 2020 Nov 15;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub4. Cochrane Database Syst Rev. 2020. PMID: 33189083 Free PMC article.
References
- Curr Alzheimer Res. 2005 Dec;2(5):541-51 - PubMed
- Int J Geriatr Psychiatry. 2006 May;21(5):449-59 - PubMed
- Arzneimittelforschung. 2007;57(1):4-11 - PubMed
- Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12197-202 - PubMed
- J Am Geriatr Soc. 1974 Mar;22(3):107-13 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical